What is Bexorg?
Bexorg is a pioneering biotechnology firm dedicated to transforming central nervous system (CNS) drug discovery and development. At the heart of its operations is the BrainEx platform, an integrated, whole-human brain system that represents a significant leap forward in neuroscientific research. By combining this platform with advanced artificial intelligence models, Bexorg provides a clinically predictive environment that addresses some of the most complex challenges in modern medicine. Founded by Dr. Zvonimir Vrselja and Dr. Nenad Sestan at Yale University, the company operates at the intersection of deep tech and bioethics, maintaining a rigorous framework to ensure the integrity of its scientific advancements. Its market position is defined by its unique ability to simulate human brain responses, offering a high-fidelity alternative to traditional drug testing methodologies.
How much funding has Bexorg raised?
Bexorg has raised a total of $23M across 1 funding round:
Series A
$23M
Series A (2025): $23M with participation from Little Engine Ventures, Amplify Partners, Connecticut Innovations, and Starbloom Capital
Key Investors in Bexorg
Amplify Partners
Amplify Partners invests in early-stage companies pioneering novel applications in machine intelligence and computer science, leveraging deep domain expertise to support technical founding teams.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm, providing equity and debt financing to help innovative companies in sectors like AI and biosciences scale effectively.
Starbloom Capital
Starbloom Capital focuses on breakthrough innovations in neuroAI, longevity, and deep tech, partnering with visionary founders to push the frontiers of science and human potential.
What's next for Bexorg?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the capabilities of the BrainEx platform and deepening the integration of its AI models. As the company moves through its current growth phase, the focus will shift toward establishing key partnerships with pharmaceutical entities and scaling its internal research capacity. The backing from specialized venture capital firms suggests a long-term commitment to pushing the frontiers of neuroAI and longevity science. Bexorg is expected to prioritize the validation of its predictive models in clinical settings, which will be essential for securing future regulatory milestones and commercializing its drug discovery pipeline. The company's trajectory indicates a clear intent to become a foundational player in the next generation of CNS therapeutics.
See full Bexorg company page
